Keyword: Celgene

Only days after Celgene dodged a U.S. patent attack on its megablockbuster drug Revlimid, a copycat has rolled onto the market in Europe.

Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.

Starboard Value is “certainly interested in the story at Bristol-Myers,” according to its leader. But that doesn’t mean it’s getting involved.

Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $74 billion Celgene deal. And an activist may be joining that list.

On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to buy Celgene. But it ended up striking a better deal instead.

Ever wish you could be a fly on the wall at a company in the middle of a merger? Thanks to the Securities and Exchange Commission, you can.

A bipartisan push to lower drug prices could threaten the industry's ability to drive earnings growth, some analysts warn.

BMS execs faced a tough audience during its Q4 report, as analysts pressed them for details about how the Celgene merger would drive growth.

Roche has the pipeline it needs for growth, its chairman said, but the company could add on with small- or medium-sized M&A.

Past pharma mergers have spawned price hikes, two U.S. representatives argue—and DTC and DOJ need to weigh the $74 billion deal with that in mind.